News|Articles|August 2, 2024

Cardiology Month in Review: July 2024

The July 2024 cardiology month in review spotlights new data from obicetrapib, a deep dive into risk stratification algorithms, and studies on the need for optimal care.

With the halfway point of the year behind them, the cardiology community has found themselves as the recipient of a plethora of breakthroughs and advances during the first half of 2024, which included historic approvals such as semaglutide for reducing cardiovascular risk in obesity, bempedoic acid’s primary prevention indication, and the first new mechanism for an oral antihypertensive in nearly 40 years.